Company intelligence / Profile preview
Corbus Pharmaceuticals Holdings, Inc.
Norwood, Massachusetts, United Statescorbuspharma.com ↗
- Ownership
- Public · CRBP
- Development stage
- Other
01
Overview
Corbus has completed enrollment of the dose escalation part of its Phase 1 clinical trial for CRB-701 with data expected in Q1 2025. The company also dosed the first patient in a Phase 1 clinical study of CRB-913 for obesity treatment in March 2025.
- Therapeutic areas
- PulmonologyRheumatologyEndocrinologyImmunologyOncology
- Modalities
- Antibody Drug Conjugate (ADC)Monoclonal antibodiesCannabinoid receptor agonistsCB1 Inverse Agonist
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
CSPC Pharmaceutical Group
04
Financials
- Market cap
- $55.3M
- Total revenue
- $0
- Enterprise value
- $-58.4M
Beyond the preview
Go deeper on Corbus Pharmaceuticals Holdings, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Corbus Pharmaceuticals Holdings, Inc..